

**DISPENSE AS WRITTEN (DAW)/  
MEMBER-PAY-THE-DIFFERENCE  
PENALTY WAIVER  
PRESCRIBER FAX FORM**

**ONLY the prescriber may complete this form. This form is for prospective, concurrent, and retrospective reviews. By submitting this form, you attest that all information provided is true and accurate.**

PLEASE NOTE: Incomplete forms will be returned for additional information.

To ensure you are submitting this form correctly, complete and submit it directly to Prime Therapeutics (see details at the end of this form) or submit it online at [www.covermymeds.com](http://www.covermymeds.com). For formulary information, please visit [www.myprime.com](http://www.myprime.com).

**PATIENT AND INSURANCE INFORMATION**

Today's date: \_\_\_\_\_

Patient First Name:	Patient Last Name:	MI:	DOB (mm/dd/yyyy):
Patient Street Address:	City, State:	ZIP:	Patient Phone:
Member ID Number:	Group Number:		

**PRESCRIBER/CLINIC INFORMATION**

Prescriber First Name:	Prescriber Last Name:	NPI:	Specialty:
Clinic Name:	Contact Name:	Phone:	Secure Fax:
Clinic Street Address:	City, State:	ZIP:	

**RENDERING/SERVICING PRESCRIBER INFORMATION (IF APPLICABLE)**

Prescriber First Name:	Prescriber Last Name:	NPI:	Specialty:
Clinic Name:	Contact Name:	Phone:	Secure Fax:
Clinic Street Address:	City, State:	ZIP:	

**MEDICAL INFORMATION. PLEASE ATTACH ADDITIONAL INFORMATION AS NEEDED.**

Patient Diagnosis with ICD-9 Code:	ICD-10 Code:
Medication and Strength Requested:	
Dosing Schedule:	Quantity per Month:

**ALL REQUESTS**

Is the patient currently being treated with the requested agent? .....  Yes  No

Is the generic drug subject to an on-going shortage confirmed by the American Society of Health-System Pharmacists (ASHP) for the Food and Drug Administration (FDA)? .....  Yes  No

**INITIAL REQUESTS**

Has the prescriber indicated on the prescription "Dispense As Written (DAW)"? .....  Yes  No

Has the patient tried an AB-rated generic equivalent to the brand agent? .....  Yes  No

Does the patient have a documented allergic reaction to an inactive ingredient that is present in the generic formulation but absent in the brand name equivalent? .....  Yes  No

If no, has the patient had a documented side effect or adverse event to a generic medication that did not occur with the brand name equivalent? .....  Yes  No

**Please continue to the next page.**

Patient First Name:	Patient Last Name:	MI:	DOB (mm/dd/yyyy):
---------------------	--------------------	-----	-------------------

Has the prescriber documented that the patient experienced an adverse event to the generic formulation on an FDA MedWatch Adverse Event Reporting Form and submitted that form to the FDA on behalf of this patient? .....  Yes  No

**If yes: Documentation including a copy of the MedWatch Adverse Event Reporting form is required.**

**RENEWAL REQUESTS**

Was the patient previously approved for the requested agent through the Florida Blue member-pay-the-difference (MPTD) penalty waiver review process? .....  Yes  No

**If no**, please complete the Initial Requests section.

Is the patient compliant with the requested agent in the past 120 days? .....  Yes  No

**If yes:** Please explain: \_\_\_\_\_

**Please indicate:**

- Date of service (if applicable): (mm/dd/yyyy): \_\_\_\_\_
- Start of treatment: Start date (mm/dd/yyyy): \_\_\_\_\_
- Continuation of therapy: Date of last treatment (mm/dd/yyyy): \_\_\_\_\_

**What is the priority level of this request?**

- Standard
- Urgent (NOTE: Urgent is defined as when the prescriber believes that waiting for a standard review could seriously harm the patient's life, health, or ability to regain maximum function.)

**If yes:** Please specify: \_\_\_\_\_

**Please fax or mail this form to:**

Prime Therapeutics LLC  
 Clinical Review Department  
 2900 Ames Crossing Road  
 Eagan, MN 55121

**CONFIDENTIALITY NOTICE:** This communication is intended only for the use of the individual entity to which it is addressed, and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 888-271-3183, and return the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.

**TOLL FREE**

**FAX: 855-212-8110    PHONE: 888-271-3183**